Baillie Gifford & CO Ultragenyx Pharmaceutical Inc. Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.5MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$427 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$241 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$220 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$179 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$132 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.01B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...